Keros Therapeutics Inc (KROS) - Total Assets
Based on the latest financial reports, Keros Therapeutics Inc (KROS) holds total assets worth $742.78 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check cash flow reinvestment rate of Keros Therapeutics Inc to assess the company's total reinvestment commitment from operating cash flow.
Keros Therapeutics Inc - Total Assets Trend (2018–2024)
This chart illustrates how Keros Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. Check KROS cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
Keros Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Keros Therapeutics Inc's total assets of $742.78 Million consist of 95.6% current assets and 4.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 90.9% |
| Accounts Receivable | $4.46 Million | 0.7% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2024)
This chart illustrates how Keros Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see KROS company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Keros Therapeutics Inc's current assets represent 95.6% of total assets in 2024, an increase from 93.1% in 2018.
- Cash Position: Cash and equivalents constituted 90.9% of total assets in 2024, up from 84.9% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is accounts receivable at 0.7% of total assets.
Keros Therapeutics Inc Competitors by Total Assets
Key competitors of Keros Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SHG:603392
|
China | CN¥13.76 Billion |
|
Amicus Therapeutics Inc
NASDAQ:FOLD
|
USA | $949.87 Million |
|
China Resources Boya Bio pharmaceutical Group Co Ltd
SHE:300294
|
China | CN¥8.41 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥772.57 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Yantai Zhenghai Bio-Tech Co Ltd
SHE:300653
|
China | CN¥964.85 Million |
|
Jiangsu GDK Biotechnology Co Ltd
SHG:688670
|
China | CN¥1.48 Billion |
Keros Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 29.86 | 19.03 | 37.27 |
| Quick Ratio | 29.86 | 19.03 | 37.06 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $695.22 Million | $523.04 Million | $260.54 Million |
Keros Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Keros Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.72 |
| Latest Market Cap to Assets Ratio | 0.54 |
| Asset Growth Rate (YoY) | 66.4% |
| Total Assets | $615.89 Million |
| Market Capitalization | $334.52 Million USD |
Valuation Analysis
Below Book Valuation: The market values Keros Therapeutics Inc's assets below their book value (0.54x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Keros Therapeutics Inc's assets grew by 66.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Keros Therapeutics Inc (2018–2024)
The table below shows the annual total assets of Keros Therapeutics Inc from 2018 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $615.89 Million | +66.44% |
| 2023-12-31 | $370.02 Million | +20.62% |
| 2022-12-31 | $306.78 Million | +20.19% |
| 2021-12-31 | $255.25 Million | -5.27% |
| 2020-12-31 | $269.44 Million | +2359.54% |
| 2019-12-31 | $10.96 Million | -60.04% |
| 2018-12-31 | $27.41 Million | -- |
About Keros Therapeutics Inc
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias… Read more